**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript NO: 8125**

**Columns: Topic Highlights**

WJG 20th Anniversary Special Issues (5): Colorectal cancer

**Prognostic and predictive response factors in colorectal cancer patients: between hope and reality**

De Divitiis C *et al*. Prognostic factors in colorectal cancer patients

Chiara De Divitiis, Guglielmo Nasti, Massimo Montano, Rossella Fisichella, Rosario Vincenzo Iaffaioli, Massimiliano Berretta

**Chiara De Divitiis, Guglielmo Nasti, Massimo Montano, Rosario Vincenzo Iaffaioli,** Medical Oncology, Abdominal Department, National Cancer Institute G. Pascale Foundation, 80131 Napoli, Italy

**Rossella Fisichella,** Department of Surgery, University of Catania, Policlinico Universitario “G. Rodolico”, 95123 Catania, Italy

**Massimiliano Berretta,** Department of Medical Oncology, National Cancer Institute of Aviano, 33081 Aviano, Italy

**Massimiliano Berretta,** Euro-Mediterranean Institute of Science and Technology (IEMEST), 90139 Palermo, Italy

**Author contributions**: De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV and Berretta M contributed equally to this work, designing and performing the research, and writing the paper.

**Correspondence to: Massimiliano Berretta, MD,** Department of Medical Oncology, National Cancer Institute of Aviano, Via Franco Gallini 2, 33081 Aviano (PN), Italy. mberretta@cro.it

**Telephone:** +39-95-7179966 **Fax:** +39-95-3782912

**Received:** December 16, 2013 **Revised:** March 13, 2014

**Accepted:** August 13, 2014

**Published online:**

**Abstract**

Colorectal cancer (CRC) represents one of the most commonly diagnosed cancers worldwide. It is the second leading cause of cancer death in Western Countries. In the last decade the survival of patients with metastatic CRC has improved dramatically. Due to the advent of new drugs (irinotecan and oxaliplatin) and target therapies (i.e., bevacizumab, cetuximab and panitumab), the median overall survival has risen from about 12 mo in the mid Nineties to 30 mo recently. Many questions needing of right collocations and more clearness still exist regarding the prognostic factors and the predictive factors of response to therapy. Despite advances in dosing and scheduling of chemotherapy in both adjuvant and advanced settings, and a greater emphasis on early detection, the outlook still remains poor for most patients. Molecular analyses have shown that the natural history of all CRCs is not the same. Individual patients with same stage tumours may have different long term prognosis and response to therapy. In addition, some prognostic variables are likely to be more important than others. Here we review the role of prognostic factors and predictive factors according to the recently published English literature.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words**: Colorectal cancer; Prognosis; Prognostic factors; Therapy; Metastases; Molecular analyses

**Core tip:** Colorectal cancer (CRC) represents one of the most commonly diagnosed cancers worldwide. It is the second leading cause of cancer death in Western Countries. In the last decade the survival of patients with metastatic CRC has improved dramatically. Due to the advent of new drugs and target therapies the median overall survival has risen from about 12 mo in the mid Nineties to 30 mo recently. Many questions still exist regarding the prognostic factors and the predictive factors of response to therapy needing of right collocations and more clearness.

De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Over the past 30 years, there has been a great interest in clinical and molecular prognostic factors in metastatic (m) colorectal cancer (CRC).

This interest is even greater today with the advent of molecularly targeted agents that have changed dramatically the treatment algorithms and the survival for patients with mCRC.

CRC is one of the most commonly diagnosed cancers in the world and remains the second leading cause of cancer death in Western countries.

Approximately 50% of patients with CRC present, at diagnosis, distant metastases. From the late 1990s the median overall survival (OS) for patients with mCRC has increased from about 12 mo, for those treated with a 5-fluorouracil (5-FU)-based chemotherapeutic regimens, to approximately 18 mo with the addition of irinotecan and oxaliplatin[1-5].

The availability of targeted biologics, in fact, next to the results obtained with chemotherapy alone, has increased the OS of mCRC to more than 24 mo, median.

The use of monoclonal antibodies such as cetuximab, panitumumab and bevacizumab has improved the treatment options ant the overall survival, but, on the other hand, has made the planning of treatment strategies increasingly articulated and complex. Furthermore, it is understood that the natural history of mCRC is not always the same; patients with mCRC may have various long term prognosis and respond differently to the same treatment. All this justifies the frantic search for biological, prognostic and predictive markers able to implement the knowledge on the biology of the tumour and drive the clinician in an increasingly personalized decision-making process.

Therefore the information on the biology of CRC, together with the identification of markers with prognostic and predictive value play today a crucial role in the management of advanced disease and in the treatment of early-stage forms, offering new tools to estimate the possibility of cure and, more generally, the overall outcome of patient.

It seems clear that the promise of personalized medicine in the treatment of mCRC is becoming a reality thanks to new knowledge of genetics that have allowed, at times, to change clinical practice.

**Clinical prognostic factors**

The extreme heterogeneity in survival rate[6], that often emerges from the results of clinical trials probably stems from the differences in the characteristics of patients and from the prognostic factors.

In addition to the Eastern Cooperative Oncology Group (ECOG) performance status (PS), patients in clinical trials are also stratified according to several prognostic factors that are likely to have a significant role in influencing their survival.

Although the analysis of several studies, most of which have not included more than 400 patients, have stressed the importance of several clinical parameters such as PS[7], or elevated levels of lactate dehydrogenase, white blood cell (WBC)[8], serum albumin [6], liver transaminases[8], haemoglobin[9], platelets, tumour markers like CEA[8] and CA 19-9 and the pathological grading[9] or various localization of the primary tumour[10], today there is no general consensus in considering each of these parameters as valid and reliable prognostic factors.

Köhne's prognostic classification is based on ECOG PS, alkaline phosphatase (ALP) level, number of metastatic sites and WBC cells count. However, the validity and applicability of this score is not universally recognized.

In fact, while Diaz *et al*[11] demonstrated the validity of Köhne’s classification in a small number of patients treated with irinotecan- or oxaliplatin-based first-line chemotherapy, Sanoff *et al*[12], on the other hand, subsequently confirmed the validity of the score.

Also the values of ALP may have prognostic significance. In the GERCOR OPTIMOX 1 study[13], patients with increased levels of ALP (3-5 times the upper limit value) showed a median progression-free (PFS) and OS significantly reduced compared to patients with less elevated ALP values.

Regarding the prognostic value of CEA levels, while in the adjuvant setting CEA remains the best tumour marker available to be used as an independent prognostic factor and as a monitor for recurrence of disease after primary tumour resection[14], its role as prognostic factor in mCRC is unclear.

High levels of serum CEA on diagnosis has been associated with a worse prognosis in some studies, while others have found no significant correlation between CEA and prognosis.

In the mCRC, the role of CEA in relation to the expression of other molecules seems to be more interesting.

Baek *et al*[15] assessed the relationship between serpin B5 and CEA expression in CRC.

They showed that the expression of serpin B5 in 377 patients with CRC is associated with CEA levels, histology, stage, lymph node metastasis, lymphatic and perineural invasion, and especially with a reduced DFS (*p =* 0.001) and OS (*p =* 0.017 ). These results indicate that in patients with mCRC, increased levels of serpin B5 could represent a negative prognostic marker correlated with the levels of CEA.

Selcukbiricik *et al*[16] aimed to determine the prognostic role of initial CEA and CA 19-9 values in mCRC patients according to the status of *KRAS*. In particular, they have questioned whether the high initial CEA and CA 19-9 levels could be associated with the presence of *KRAS* mutation in patients with mCRC.

Between 2000 and 2010, a total of 215 patients with mCRC treated and followed up in Turkey, have been analyzed. Smokers have been excluded from the study. The clinic-pathological findings and initial CEA and CA 19-9 values have been determined.

*KRAS* mutation analysis has been performed using quantitative PCR evaluation of the DNA from the tumour tissues[17].

*KRAS* mutations have been detected in 99 of the patients (46%). *KRAS* has been found to be wild type in 116 patients (54%). Significant differences have been detected between the *KRAS* wild-type and mutant groups with respect to age and the initial serum CEA levels. The median OS time and 3-year OS rate for patients with a high initial CEA level (> 5 ng/mL) have been significantly shorter than those of patients with a low initial CEA level (< 5 ng/mL) (50.5 mo and 61.8% *vs* 78.6 mo and 79.1%, *p =* 0.014). Multivariate analysis has indicated stage at the time of diagnosis (*p <* 0.001) and low initial serum CEA level (*p =* 0.037) as independent prognostic factors of OS. For *KRAS* mutant patients, the stage at diagnosis (*p =* 0.017), low initial serum CEA level (*p =* 0.001), and low initial serum CA 19-9 level have been found to be independent prognostic indicators of OS. Thus, they have demonstrated for the first time that the presence of a *KRAS* mutation correlates with high initial CEA and CA 19-9 levels in patients with mCRC.

They concluded that the patients with high initial CEA and CA 19-9 levels may potentially predict the presence of a *KRAS* mutation, and this prediction may guide targeted therapies in these patients.

CA 19-9, which is called sialyl Lewis a (sLa), is another alternative marker for CRC[18,19].

The increase of CA 19-9 has demonstrated a significantly higher frequency of metastasis and distinctly lower survival rate, making it an adverse prognostic factor for CRC patients[19].

It is commonly accepted that CA 19-9 is used as a marker of hematogenous metastasis and a predictor of prognosis in CRC[20]. However, the significance of elevated CA 19-9 in CRC remains to be clarified. Forexample, the increase of CA 19-9 has been reported as a riskfactor for extra hepatic metastasis in CRC patients withliver metastasis (LM)[21]. For CRC patientswith normal CEA, CA 19-9 has been a valuable prognosticfactor and might help predict lung metastasis[22]. Elevated CA 19-9 has also been reported to be relatedwith the peritoneal metastasis (PM) of CRC[23].

Furthermore, both CEA and CA19-9 have been found to beindependent and significant predictors for OSin unresectable CRC LM[24].

Dong *et al*[25] aimed to explore the value of CA 19-9, CEA and some biochemical enzymes in indicating LM of CRC.

A total of 493 patients with metastatic cancers have been retrospectively evaluated. Three groups of eligible patients have been identified: CRC patients with LM (CRC-LM) or without LM (CRCNLM), and non-CRC patients with LM (NCRC-LM). All metastatic lesions have been identified by CT or MRI. Data on characteristics of the patients, the primary site, the locations of metastasis, CA 19-9, CEA, and biochemical parameters have been collected for analysis.

Some biochemical enzymes have been found to be significantly higher in groups with LM than without CRC-LM or NCRC-LM *vs* CRC-NLM. Both CEA and CA 19-9 resulted much higher in CRC-LM than CRC-NLM or NCRC-LM. For CRC patients, CA 19-9, γ-glutamyl transpeptidase, CEA and alcohol consumption have been identified as independent factors associated with LM.

This analysis has suggested that CA 19-9 might be a potential valuable indicator for LM of CRC in the clinic.

Recently some authors have reported that the concomitant diagnosis of HIV-infection and CRC represents an independent and poor prognostic factor in this particular setting of patients[26-29].

Conversely old age does not represent, after accurate evaluation (Comprehensive Geriatric Assessment) of elderly CRC patient, a poor prognostic factor[30-35].

**Histology**

Regarding the histology, the majority of CRC is represented by adenocarcinomas.

The variants "Mucinous" and "signet ring" adenocarcinoma, have a poor prognosis[36], and constitute approximately 10%, with signet ring cell carcinoma comprising 1%-2.4%. Mucinous cancers are characterized by the presence of abundant extracellular mucin, (more than 50% of the tumour mass).

Not only patients with mucinous mCRC have a poor prognosis, but they also have reduced response to chemotherapy and targeted agents[37].

Therefore, this pathological feature can be considered as prognostic markers and used as a stratification factor for clinical trials in mCRC.

**peritoneal involvement**

The peritoneal involvement is an important independent pathological prognostic parameter and may supersede other parameters in current usage in CRC prognosis.

The prognosis of these patients is poor with reduced survival from 18.1 mo to 6.7 mo from[38]. Often they present at diagnosis with PS expired, ascites and weight loss. The goal of treatment in this case is therefore palliation, reserving the systemic chemotherapy when the diagnosis is made before surgery.

In fact, surgery or chemotherapy alone do not improve the patients' survival and results in a median survival of 5-7 mo. In recent years, a new therapeutic alternative approach based on the combination of surgery with chemotherapy has been developed as a treatment for peritoneal disease.

Some studies[39,40] indicated that the only real treatment options to improve the survival of patients with peritoneal disease at the time seem to be represented by the cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)[39]. But it must be considered that these procedures are burdened with significant morbidity and mortality. It is therefore essential a careful selection of the patients that can actually tolerate and benefit from these types of treatments rather aggressive. In any case the prognosis in these patients is conditioned by the extents of carcinomatosis, by Sugarbaker's peritoneal cancer index (PCI), by the possibility of obtaining a complete cytoreduction and by the opportunity to perform a postoperative systemic chemotherapy.

**Molecular prognostic and predictive markers**

In order to accurately treat the molecular markers (prognostic and predictive) it must be remembered that the development of CRC is a multistep and complex process. It occurs as a result of the accumulation of different and many genetic and epigenetic alterations that negatively affect the process of regulation, control of cell proliferation and differentiation, apoptosis, and angiogenesis.

***KRAS-NRAS-BRAF***

While the expression of EGFR and the presence of *EGFR* gene mutations do not appear related to therapeutic response, the determination of the status of *KRAS* gene plays a crucial role. The presence of mutations allows the protein of the *KRAS* to meet a constitutive activation and therefore to be active also when it is blocked the activity of EGFR. In CCR, *KRAS* mutations are found in 35%-45% of cases, and usually (> 90% of cases) are borne by the codons 12 and 13, more rarely codon 6.

The role of *KRAS* mutations as a prognostic factor independent of treatment seems unlikely but it is still controversial.

Approximately 35% CRC tissues carry a mutation at codon 12 (25%) or 13 (10%) of *KRAS* that leads to the constitutive activation of EGFR downstream pathways[44–48].

Information on the *KRAS*/*BRAF* genotype is also extremely useful when selecting systemic chemotherapy for advanced and recurrent patients with CRC, because it can help identify patients with poor prognoses. *KRAS* and *BRAF* are currently under focus as potential prognostic and predictive biomarkers in patients with metastatic diseases treated with anti-EGFR monoclonal antibodies (mAb), such as cetuximab and panitumumab[49-53].

Several retrospective analyses revealed that cetuximab treatment is ineffective in patients with *KRAS* mutations, thereby suggesting that the *KRAS* genotype is a useful predictive biomarker for cetuximab or panitumumab therapy in CRC. It has also been suggested that wild-type *BRAF* is required for a successful response to panitumumab or cetuximab therapies in patients with metastatic CRC. However, the prognostic relevance of the *KRAS* genotype in CRC remains controversial despite several multi-institutional investigations since the 1990s[54-57].

The activation of EGFR signalling, such as Ras/Raf/MAP/ MEK/ERK and/or PTEN/PI3K/Akt pathways, constitutes a key step in tumourigenesis and the tumour progression of CRC[58]. Two predominant EGFR inhibitors have been developed including monoclonal antibodies that target the extracellular domain of EGFR and small molecule TKIs that target the receptor catalytic domain of EGFR. Although both classes of agents show clear anti-tumour activity, only the anti-EGFR mAb has been approved for clinical use in the treatment of patients with mCRC. Because the predictive value of alterations in EGFR expression level is unclear in the use of anti-EGFR mAb, the focus has shifted to alterations of key signalling pathways downstream of EGFR. In particular, *KRAS* and *BRAF* mutations have been studied as the activating mechanisms of the EGFR signalling pathway. Screening for *KRAS*/*BRAF* genotype is extremely important for identifying patients with shorter survival in response to systemic chemotherapy, regardless of the use of anti-EGFR mAb, and for predicting patients who would benefit from anti-EGFR mAb therapy. Therefore, the significance of *KRAS*/*BRAF* mutations as prognostic and/or predictive biomarkers in patients with CRC should be considered while selecting a method for *KRAS* genotyping. The *KRAS* genotype is a useful predictive biomarker for patients with metastatic CRC being treated with anti-EGFR mAb. Several studies have showed the possibility that *KRAS13* may have a specific phenotype different from other *KRAS* genotypes. Therefore, differences in *KRAS* mutations at codons 12 and 13 may result in different biological, biochemical, and functional consequences and clinical features, which may also influence the prognosis of CRC. In fact, a lot of retrospective analyses have suggested that *KRAS* mutations at codon 13, particularly *KRAS* p.G13D, as well as *BRAF* mutations are prognostic factors.

In particular, Tejpar *et al*[59],in pooled data from 1,378 evaluable patients from the CRYSTAL and OPUS studies, have investigated the associations between tumour *KRAS* mutation status (wild-type, G13D, G12V, or other mutations) and PFS, OS, and response. Significant variations in treatment effects have been found for tumour response (*P =* 0.005) and PFS (*P =*0.046) in patients with G13D-mutant tumours versus all other mutations (including G12V). Within *KRAS* mutation subgroups, cetuximab plus chemotherapy versus chemotherapy alone have significantly improved PFS [median, 7.4 *vs* 6.0 mo; hazard ratio (HR) = 0.47; *P =*0.039] and tumour response (40.5% *vs* 22.0%; OR = 3.38; *P =* 0.042) but not OS (median, 15.4 mo *vs* 14.7 mo; HR = 0.89; *P =* 0.68) in patients with G13D-mutant tumours. Patients with G12V and other mutations did not benefit from this treatment combination. Patients with *KRAS* G13D–wilde tumours receiving chemotherapy alone experienced worse outcomes (response, 22.0% *vs* 43.2%; OR = 0.40; *P =* 0.032) than those with other mutations. Effects were similar in the separate CRYSTAL and OPUS studies. The authors concluded that the addition of cetuximab to first-line chemotherapy confers a benefit to patients with *KRAS* G13D–mutant tumours. These findings also suggested that patients with CRC having *KRAS* mutations constitute a heterogeneous population. Since the prognostic and/or predictive role of *KRAS13* mutations continues to remain controversial, further prospective clinical investigations are warranted. Also, *KRAS* wild-type status is an imperfect predictor of sensitivity to anti-EGFR monoclonal antibodies in CRC, motivating efforts to identify novel molecular aberrations driving RAS. The identification of *KRAS* mutations as markers of resistance to EGFR inhibitors has paved the way to the interrogation of numerous other markers of resistance to anti-EGFR therapy, such as *NRAS*, *BRAF*, and PI3KCA mutations. Other genomic and protein expression alterations have been recently identified as potential targets of treatment or as markers of chemotherapy or targeted-therapy resistance, including ERCC1 expression, c-Met expression, PTEN expression, HER2 amplification, HER3 expression, and rare *KRAS* mutations. As the number of distinct validated intra-tumour genomic assays increases, numerous molecular assays will need to be compiled into one multigene panel assay.

Mutations in *KRAS* account for about 85% of all *RAS* mutations in human tumours, *NRAS* for about 15%, and *HRAS* for less than 1%[12]. Which particular *RAS* gene is mutated seems tobe tumour specific; colonic, pancreatic and lung cancers have high frequencies of *KRAS* mutations. Nevertheless, there are only a few reports on *NRAS* mutations in CRC and none of these studies correlated *RAS* mutations with other molecular events. Natsumi Irahara, *et al*[58] developed and validated a Pyroseqencing assay to detect *NRAS* mutations at codons 12, 13 and 61 and, utilizing a collection of 225 CRCs from two prospective cohort studies, the authors examined the relationship between *NRAS* mutations, clinical outcome, and other molecular features, including mutation of *KRAS*, *BRAF*, and *PIK3CA*, microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP). Finally, they examined whether *NRAS* mutation was associated with patient survival or prognosis. *NRAS* mutations were detected in 5 (2.2%) of the 225 CRCs and tended to occur in left-sided cancers arising in women, but did not appear to be associated with any of the molecular features that were examined[58].

Several researches have suggested that tumours harbouring *BRAF* mutations have distinct clinic-pathological features compared with tumours harbouring *KRAS* mutations. Souglakos and associates demonstrated that *BRAF* mutations in primary CRC mark patients with poor prognosis regardless of specific treatment regimen[47]. Patients with *BRAF* mutation had significantly higher likelihood of disease progression (*P <* 0.0001) or death (*P <* 0.0001) with any treatment regimen. The *BRAF* V600E mutation predicted independently early relapse on first-line therapy and death. It was deduced that *BRAF* mutation does not simply substitute for *KRAS* activation in a linear signalling pathway but probably confers distinct impact on prognosis. It also suggests that *KRAS* mutation may bypass aberrant EGFR signalling. In the PETACC-3 study which included stage II and stage III cancers, *BRAF* tumour mutation was found in 7.9% of cases and there was no significant variability with tumour stage. In a multivariate analysis, *BRAF* mutation was significantly associated with female sex, and highly significantly associated with right-sided tumours, older age, high grade, and MSI-high tumours. In univariate and multivariate analysis *BRAF* mutation was not prognostic for relapse free survival but was prognostic for OS, particularly in patients with MSI-L MSS tumours.

As a predictive marker, patients with *BRAF* mutant tumours treated with cetuximab had also lower PFS compared with those with *BRAF* wild type (0% *vs* 17%). In the study by Souglakos *et al*[47]in 2009, a finding which could partly explain resistance to anti EGFR targeted therapy in a subset of patients with tumours harbouring *KRAS* wild type. This is in keeping with an earlier study by Di Nicolantonio *et al*[60], where the response to panitumumab or cetuximab was found to be impeded by the presence of *BRAF* V600E mutation and restored (in a cellular model of CRC cells) by *BRAF* inhibitor sorafenib[48,60]. They suggested that this experimental observation should encourage conceiving clinical trials using multiple therapies with EGFR and *BRAF*/MAPK inhibitors, considering that cetuximab, panitumumab, and sorafenib are already approved for clinical use.

Furthermore, *BRAF* mutations are significant negative prognostic biomarkers in patients with recurrent CRC across all disease stages. Besides, the prognostic value of *BRAF* mutations has been confirmed in patients with CRC treated with specific chemotherapy regimens in clinical trials evaluating a combination of cetuximab with chemotherapy. However, whether *BRAF* mutations are negative predictive biomarkers for anti-EGFR mAb has not been ascertained, because the controlled study, which directly compared the efficacy of adding anti-EGFR mAb to chemotherapy with that of chemotherapy alone, is lacking in a small population with *BRAF* mutations. The application of novel strategies targeting *BRAF* kinase is assured for the treatment of patients with CRC with *BRAF* mutations to improve their poor survival. However, clinical data suggest that the Ras/Raf/ERK pathway is insufficient for completely predicting the response to anti-EGFR mAbs. Thus, other factors, such as PIK3CA/PTEN deregulation and/or the expression status of epiregulin or amphiregulin, should also be studied on as possible predictive biomarkers for anti-EGFR mAb.

In line with these new evidence, Douillard *et al*[61] have suggested that mutations in exons 3 and 4 *KRAS* and exons 2, 3 and 4 of *NRAS* represent factors of possible resistance to panitumumab. In particular, the population of patients with metastatic CRC defined as “all ras wild type”, presented in the study PRIME a significant advantage in survival [(OS was 26.0 mo in the panitumumab-FOLFOX4 group *vs* 20.2 mo in the FOLFOX4-alone group (HR for death, 0.78; 95% CI: 0.62-0.99; *P =* 0.04)] with the use of panitumumab in combination with FOLFOX compared to chemotherapy alone. Also, the analysis of the survival data showed a detrimental effect of this combination in the population of patients "all mutated *RAS*". Finally, the PRIME study confirmed the strong negative prognostic role of *BRAF* mutations, although these have not shown a clear predictive effect related to anti EGRF therapies.

**PTEN**

Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) negatively regulate the phosphoinositide-3-kinase (PI3K) signalling pathway.

PI3KCA mutation and PTEN deletion could explain the resistance to anti EGFR therapy (for example to cetuximab or panitumumab).

Atreya *et al*[62], analysed the frequency with which PTEN was lost, the degree of agreement by which PTEN was expressed in the primary tumour (70 human CRC) and metastatic sites (in particular LMs) and the possible prognostic significance of the expression of PTEN in the cases of CRC.

The results of this analysis showed a loss of PTEN expression in 12.3% of primary CRC and in 10.3% of liver metastases, with 98% of correlation between the expression of PTEN in primary tumour and in LMs.

In addition, the authors found a significant relationship between the lack of expression of PTEN and an increased risk of death, thus highlighting the possible role of PTEN loss as a marker of poor outcome in patients with CRC.

Currently, conflicting information exists regarding Her-2 over-expression and its clinic-pathological implications in CRC. Lim *et al*[63], determined Her-2 over-expression in both serum and tumour tissue of ninety five CRC patients by chemiluminescent immunoassay and immune-histochemical staining. The results were confirmed using fluorescent in situ hybridization. Clinico-pathological parameters were analyzed according to Her-2 expression status. They founded that serum Her-2 levels were not significantly associated with prognostic parameters. They concluded that Her-2 expression analysis of CRC tissue, but not in serum, acts as a significant independent worse prognostic factor. Then, the assessment of Her-2 expression status may be valuable for the targeted therapeutic management of CRC.

Karagkounis *et al*[64], studied the frequency and prognostic value of KRAS and BRAF mutations in subjects with CRC and LMs undergoing surgery for LMs. Therefore, the results that emerge from their analysis indicate that molecular markers such as KRAS may have a role in prognostic evaluation of patients undergoing surgery of LMs from colorectal CRC.

**predictive value of early metabolic PET/CT response**

With the availability of many new drugs and molecular targeted becomes stronger and stronger the need for the medical oncologist to obtain information that can somehow predict the effectiveness of a treatment or giving information on a possible response to the same.

Today, more than by the methods of traditional radiology, the nuclear medicine techniques such as 18 F - FDG seem meet part of these new needs of oncologist. Especially Lastoria *et al*[65] showed as early changes in tumour metabolism measured by positron emission tomography/computed tomography with 18 F–FDG could serve as prognostic indicators of a response to chemotherapy in an earlier and more accurate assessment can be obtained with the classical RECIST criteria.

In their experience, the authors analyzed 33 patients with resectable LM from CRC, within a phase 2 trials of preoperative FOLFIRI plus bevacizumab. A PET/CT evaluation was performed before and after one cycle of FOLFIRI plus bevacizumab. They concluded that, in patients with resectable LMs from CRC underwent preoperative chemotherapy, a good metabolic response obtained with PET was predictive of improved long-term survival. Clearly, larger studies are needed to confirm these results.

Recently, Celik *et al*[66], showed that in proteomics models of mCRC patients treated with bevacizumab, sTRAIL (TNF-related apoptosis-inducing ligand-) and CXCL8 could indicate tumour response and survival according to the metabolic responses obtained with FDG-PET.

**CONCLUSION**

This report of prognostic and predictive factors of mCRC is by no means exhaustive, but wants to provide an overview of the topic to help guide the management of these patients.

In fact, at the current state of knowledge, it does not seem possible to precisely identify any bio – molecular - prognostic or predictive factor, with a clinical validity established and standardized. Despite this, the identification of several molecular factors that have prognostic significance in CRC will be essential in improving the treatment and outcome of the disease. It is possible to envisage that, rather than a single marker, identification a "molecular profile of risk," resulting from the analysis of several molecular markers, should be developed and may have a more precisely clinical, prognostic and therapeutic value.

From the foregoing, it is clear how ongoing studies and strategies to identify prognostic and predictive markers of outcome of patients with CRC are always the most intriguing and the object of interest by many researchers.

Molecular techniques, studies and pharmacogenomics[67-70] are helping develop a considerable number of new therapeutic strategies. This new knowledge will enrich and clarify the valuable information arising histological examination. Moreover, to better understand the interpretation of prognostic factors and predictive factors response to therapy, these results have been summarized and reported in tables 1 and 2.

Obviously, further studies are needed to better define the prognostic information allowing them to become important criteria to select patients who will benefit from the several drugs available.

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* ; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Dušek J**, Mužík D. Epidemiology of colorectal cancer: international comparison. Malúšková L. Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic

3 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [online]. International Agency for Research on Cancer, Lyon (France) 2010. Available from: URL: http: //globocan.iarc.fr

4 **Ferlay J**, Parkin DM, Curado MP, Bray F, Edwards B, Shin HR, Forman D. Cancer Incidence in Five Continents, Volumes I to IX: IARC CancerBase No. 9 [online]. International Agency for Research on Cancer, Lyon (France) 2010. Available from: URL: http: //ci5.iarc.fr

5 **Ferlay J**, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. *Ann Oncol* 2007; **18**: 581-592 [PMID: 17287242 DOI: 10.1093/annonc/mdl498]

6 **Köhne CH**, Kretzschmar A, Wils J. First-line chemotherapy for colorectal carcinoma—we are making progress. *Onkologie* 1998; **21**: 280–289 [DOI: 10.1159/000026851]

7 **Steinberg SM**, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. *Cancer* 1986; **57**: 1866-1870 [PMID: 3485470 DOI: 10.1002/1097-0142(19860501)57:9<1866::AID-CNCR2820570928>3.0.CO;2-T]

8 **Kemeny N**, Braun DW. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. *Am J Med* 1983; **74**: 786-794 [PMID: 6837602 DOI: 10.1016/0002-9343(83)91066-5]

9 **Graf W**, Bergström R, Påhlman L, Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. *Eur J Cancer* 1994; **30A**: 453-457 [PMID: 8018402 DOI: 10.1016/0959-8049(94)90417-0]

10 **Graf W**, Glimelius B, Påhlman L, Bergström R. Determinants of prognosis in advanced colorectal cancer. *Eur J Cancer* 1991; **27**: 1119-1123 [PMID: 1835620 DOI: 10.1016/0277-5379(91)90307-Y]

11 **Díaz R**, Aparicio J, Gironés R, Molina J, Palomar L, Segura A, Montalar J. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. *Clin Colorectal Cancer* 2005; **5**: 197-202 [PMID: 16197623 DOI: 10.3816/CCC.2005.n.031]

12 **Sanoff HK**, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. *J Clin Oncol* 2008; **26**: 5721-5727 [PMID: 19001325 DOI: 10.1200/JCO.2008.17.7147]

13 **Chibaudel B**, Tournigand C, Artru P, André T, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Rivera F, Perez-Staub N, Louvet C, de Gramont A. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. *Ann Oncol* 2009; **20**: 1383-1386 [PMID: 19465426 DOI: 10.1093/annonc/mdp012]

14 **Wang JY**, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. *Dis Colon Rectum* 1994; **37**: 272-277 [PMID: 8137675 DOI: 10.1007/BF02048166]

15 **Baek JY**, Yeo HY, Chang HJ, Kim KH, Kim SY, Park JW, Park SC, Choi HS, Kim DY, Oh JH. Serpin B5 is a CEA-interacting biomarker for colorectal cancer. *Int J Cancer* 2014; **134**: 1595-1604 [PMID: 24114705 DOI: 10.1002/ijc.28494]

16 **Selcukbiricik F**, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, Demirelli F, Serdengecti S. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? *Tumour Biol* 2013; **34**: 2233-2239 [PMID: 23625655 DOI: 10.1007/s13277-013-0763-6]

17 **Marzouk O**, Schofield J. Review of histopathological and molecular prognostic features in colorectal cancer. *Cancers (Basel)* 2011; **3**: 2767-2810 [PMID: 24212832 DOI: 10.3390/cancers3022767]

18 **Kannagi R**, Kitahara A, Itai S, Zenita K, Shigeta K, Tachikawa T, Noda A, Hirano H, Abe M, Shin S. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl-fucosyl type 1 chain. *Cancer Res* 1988; **48**: 3856-3863 [PMID: 2454154]

19 **Levy M**, Visokai V, Lipska L, Topolcan O. Tumor markers in staging and prognosis of colorectal carcinoma. *Neoplasma* 2008; **55**: 138-142 [PMID: 18237252]

20 **Takada A**, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. *Cancer Res* 1993; **53**: 354-361 [PMID: 7678075]

21 **Sasaki A**, Kawano K, Inomata M, Shibata K, Matsumoto T, Kitano S. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma. *Hepatogastroenterology* 2005; **52**: 1814-1819 [PMID: 16334783]

22 **Lin PC**, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Li AF, Chen WS, Chang SC. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. *Int J Colorectal Dis* 2012; **27**: 1333-1338 [PMID: 22426691 DOI: 10.1007/s00384-012-1447-1]

23 **Yang SH**, Lin JK, Lai CR, Chen CC, Li AF, Liang WY, Jiang JK. Risk factors for peritoneal dissemination of colorectal cancer. *J Surg Oncol* 2004; **87**: 167-173 [PMID: 15334631 DOI: 10.1002/jso.20109]

24 **Mitsuyama Y**, Shiba H, Haruki K, Fujiwara Y, Furukawa K, Iida T, Hayashi T, Ogawa M, Ishida Y, Misawa T, Kashiwagi H, Yanaga K. Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis. *Oncol Lett* 2012; **3**: 767-771 [PMID: 22740990]

25 **Dong H**, Tang J, Li LH, Ge J, Chen X, Ding J, Men HT, Luo WX, Du Y, Li C, Zhao F, Chen Y, Cheng K, Liu JY. Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases. *Asian Pac J Cancer Prev* 2013; **14**: 909-913 [PMID: 23621260 DOI: 10.7314/APJCP.2013.14.2.909]

26 **Berretta M**, Zanet E, Basile F, Ridolfo AL, Di Benedetto F, Bearz A, Berretta S, Nasti G, Tirelli U. HIV-positive patients with liver metastases from colorectal cancer deserve the same therapeutic approach as the general population. *Onkologie* 2010; **33**: 203-204 [PMID: 20389148 DOI: 10.1159/000292126]

27 **Berretta M**, Lleshi A, Cappellani A, Bearz A, Spina M, Talamini R, Cacopardo B, Nunnari G, Montesarchio V, Izzi I, Lanzafame M, Nasti G, Basile F, Berretta S, Fisichella R, Schiantarelli C C, Garlassi E, Ridolfo A, Guella L, Tirelli U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. *Curr HIV Res* 2010; **8**: 218-222 [PMID: 20158458 DOI: 10.2174/157016210791111061]

28 **Berretta M**, Cappellani A, Di Benedetto F, Lleshi A, Talamini R, Canzonieri V, Zanet E, Bearz A, Nasti G, Lacchin T, Berretta S, Fisichella R, Balestreri L, Torresin A, Izzi I, Ortolani P, Tirelli U. Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. *Onkologie* 2009; **32**: 319-324 [PMID: 19521118 DOI: 10.1159/000215719]

29 **Berretta M**, Di Benedetto F, Bearz A, Simonelli C, Martellotta F, Del Ben C, Berretta S, Spina M, Tirelli U. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. *Cancer Invest* 2008; **26**: 610-614 [PMID: 18584352 DOI: 10.1080/07357900701781747]

30 **Di Benedetto F**, D'Amico G, Spaggiari M, Tirelli U, Berretta M. Onco-surgical management of colo-rectal liver metastases in older patients: a new frontier in the 3rd millennium. *Anticancer Agents Med Chem* 2013; **13**: 1354-1363 [PMID: 24102282 DOI: 10.2174/18715206113136660344]

31 **Berretta M**, Aprile G, Nasti G, Urbani M, Bearz A, Lutrino S, Foltran L, Ferrari L, Talamini R, Fiorica F, Lleshi A, Canzonieri V, Lestuzzi C, Borsatti E, Fisichella R, Tirelli U. Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. *Anticancer Agents Med Chem* 2013; **13**: 1344-1353 [PMID: 24102280 DOI: 10.2174/18715206113136660347]

32 **Berretta M**, Di Benedetto F, Di Francia R, Lo Menzo E, Palmeri S, De Paoli P, Tirelli U. Colorectal cancer in elderly patients: from best supportive care to cure. *Anticancer Agents Med Chem* 2013; **13**: 1332-1343 [PMID: 24102277 DOI: 10.2174/18715206113136660350]

33 **Di Benedetto F**, Berretta M, D'Amico G, Montalti R, De Ruvo N, Cautero N, Guerrini GP, Ballarin R, Spaggiari M, Tarantino G, Di Sandro S, Pecchi A, Luppi G, Gerunda GE. Liver resection for colorectal metastases in older adults: a paired matched analysis. *J Am Geriatr Soc* 2011; **59**: 2282-2290 [PMID: 22188075 DOI: 10.1111/j.1532-5415.2011.03734.x.]

34 **Berretta M**, Zanet E, Nasti G, Lleshi A, Frustaci S, Fiorica F, Bearz A, Talamini R, Lestuzzi C, Lazzarini R, Fisichella R, Cannizzaro R, Iaffaioli RV, Berretta S, Tirelli U. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). *Arch Gerontol Geriatr* 2012; **55**: 271-275 [PMID: 21937127 DOI: 10.1016/j.archger.2011.08.016]

35 **Berretta M**, Cappellani A, Fiorica F, Nasti G, Frustaci S, Fisichella R, Bearz A, Talamini R, Lleshi A, Tambaro R, Cocciolo A, Ristagno M, Bolognese A, Basile F, Meneguzzo N, Berretta S, Tirelli U. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. *Arch Gerontol Geriatr* 2011; **52**: 89-93 [PMID: 20211502 DOI: 10.1016/j.archger.2010.02.006]

36 **Mekenkamp LJ**, Heesterbeek KJ, Koopman M, Tol J, Teerenstra S, Venderbosch S, Punt CJ, Nagtegaal ID. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. *Eur J Cancer* 2012; **48**: 501-509 [PMID: 22226571 DOI: 10.1016/j.ejca.2011.12.004]

37 **Yamaguchi T**, Taniguchi H, Fujita S, Sekine S, Yamamoto S, Akasu T, Kushima R, Tani T, Moriya Y, Shimoda T. Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma. *Histopathology* 2012; **61**: 162-169 [PMID: 22448644 DOI: 10.1111/j.1365-2559.2012.04235.x]

38 **Yonemura Y**, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. *ScientificWorldJournal* 2013; **2013**: 978394 [PMID: 23710154 DOI: 10.1155/2013/978394]

39 **Teo M**. Peritoneal based malignancies and their treatment. *Ann Acad Med Singapore* 2010; **39**: 545-772

40 **Verwaal VJ**, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 2003; **21**: 3737-3743 [PMID: 14551293 DOI: 10.1200/JCO.2003.04.187]

41 **Ilyas M**, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. *Eur J Cancer* 1999; **35**: 335-351 [PMID: 10448282 DOI: 10.1016/S0959-8049(98)00431-6]

42 **Arteaga C**. Targeting HER1/EGFR: a molecular approach to cancer therapy. *Semin Oncol* 2003; **30**: 3-14 [PMID: 12840796 DOI: 10.1016/S0093-7754(03)70010-4]

43 **Arteaga CL**. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. *Semin Oncol* 2002; **29**: 3-9 [PMID: 12422308 DOI: 10.1016/S0093-7754(02)70085-7]

44 **Volgelstein B**, Kinzler KW. The genetic basis of human cancer. London (U.K.): McGraw-Hill, 1999: 565-587

45 **Wan PT**, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* 2004; **116**: 855-867 [PMID: 15035987 DOI: 10.1016/S0092-8674(04)00215-6]

46 **Benvenuti S**, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. *Cancer Res* 2007; **67**: 2643-2648 [PMID: 17363584 DOI: 10.1158/0008-5472.CAN-06-4158]

47 **Souglakos J**, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. *Br J Cancer* 2009; **101**: 465-472 [PMID: 19603024 DOI: 10.1038/sj.bjc.6605164]

48 **Karapetis CS**, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008; **359**: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]

49 **Van Cutsem E**, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; **360**: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]

50 **Bokemeyer C**, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009; **27**: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]

51 **Tol J**, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. *N Engl J Med* 2009; **361**: 98-99 [PMID: 19571295 DOI: 10.1056/NEJMc0904160]

52 **Andreyev HJ**, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. *J Natl Cancer Inst* 1998; **90**: 675-684 [PMID: 9586664 DOI: 10.1093/jnci/90.9.675]

53 **Yokota T**. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? *Anticancer Agents Med Chem* 2012; **12**: 163-171 [PMID: 22043994 DOI: 10.2174/187152012799014968]

54 **French AJ**, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. *Clin Cancer Res* 2008; **14**: 3408-3415 [PMID: 18519771 DOI: 10.1158/1078-0432.CCR-07-1489]

55 **Kakar S**, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, Kim YS. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. *Arch Pathol Lab Med* 2008; **132**: 958-964 [PMID: 18517279 DOI: 10.1043/1543-2165(2008)132[958: CCCIMP]2.0.CO; 2]

56 **Ogino S**, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. *Gut* 2009; **58**: 90-96 [PMID: 18832519 DOI: 10.1136/gut.2008.155473]

57 **Roth AD**, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J Clin Oncol* 2010; **28**: 466-474 [PMID: 20008640 DOI: 10.1200/JCO.2009.23.3452]

58 **Irahara N**, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. NRAS mutations are rare in colorectal cancer. *Diagn Mol Pathol* 2010; **19**: 157-163 [PMID: 20736745 DOI: 10.1097/PDM.0b013e3181c93fd1]

59 **Tejpar S**, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. *J Clin Oncol* 2012; **30**: 3570-3577 [PMID: 22734028 DOI: 10.1200/JCO.2012.42.2592]

60 **Di Nicolantonio F**, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 5705-5712 [PMID: 19001320 DOI: 10.1200/JCO.2008.18.0786]

61 **Douillard JY**, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013; **369**: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoa1305275]

62 **Atreya CE**, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. *Cancer Med* 2013; **2**: 496-506 [PMID: 24156022 DOI: 10.1002/cam4.97]

63 **Lim SW**, Kim HR, Kim HY, Huh JW, Kim YJ, Shin JH, Suh SP, Ryang DW, Kim HR, Shin MG. Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. *Cell Oncol (Dordr)* 2013; **36**: 311-321 [PMID: 23722824 DOI: 10.1007/s13402-013-0136-6]

64 **Karagkounis G**, Torbenson MS, Daniel HD, Azad NS, Diaz LA, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. *Cancer* 2013; **119**: 4137-4144 [PMID: 24104864 DOI: 10.1002/cncr.28347]

65 **Lastoria S**, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. *J Nucl Med* 2013; **54**: 2062-2069 [PMID: 24136935 DOI: 10.2967/jnumed.113.119909]

66 **Celik B**, Yalcin AD, Bisgin A, Dimitrakopoulou-Strauss A, Kargi A, Strauss LG. Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers. *Med Sci Monit* 2013; **19**: 875-882 [PMID: 24145180 DOI: 10.12659/MSM.889605]

67 **Di Francia R**, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, Cavaliere C, Nasti G, Facchini G, Berretta M. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. *Anticancer Drugs* 2013; **24**: 1069-1078 [PMID: 24025562 DOI: 10.1097/CAD.0000000000000002]

68 **Di Francia R**, Siesto RS, Valente D, Spart D, Berretta M. Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy. *Eur Rev Med Pharmacol Sci* 2012; **16**: 1211-1217 [PMID: 23047504]

69 **Di Francia R**, Valente D, Catapano O, Rupolo M, Tirelli U, Berretta M. Knowledge and skills needs for health professions about pharmacogenomics testing field. *Eur Rev Med Pharmacol Sci* 2012; **16**: 781-788 [PMID: 22913211]

70 **Di Francia R**, Cimino L, Berretta M. Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them. *Eur Rev Med Pharmacol Sci* 2012; **16**: 285-298 [PMID: 22530343]

71 **Sartore-Bianchi A**, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. *J Clin Oncol* 2007; **25**: 3238-3245 [PMID: 17664472 DOI: 10.1200/JCO.2007.11.5956]

72 **Khambata-Ford S**, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. *J Clin Oncol* 2007; **25**: 3230-3237 [PMID: 17664471 DOI: 10.1200/JCO.2006.10.5437]

73 **Jacobs B**, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Pénault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. *J Clin Oncol* 2009; **27**: 5068-5074 [PMID: 19738126 DOI: 10.1200/JCO.2008.21.3744]

74 **Amado RG**, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]

75 **De Roock W**, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. *JAMA* 2010; **304**: 1812-1820 [PMID: 20978259 DOI: 10.1001/jama.2010.1535]

76 **Bokemeyer C**, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol* 2011; **22**: 1535-1546 [PMID: 21228335 DOI: 10.1093/annonc/mdq632]

77 **De Roock W**, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; **11**: 753–762 [DOI: 10.1016/S1470-2045(10)70130-3]

78 **Seymour MT**, Brown SR, Richman S, Middleton GW, Maughan T, Olivier C. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). *J Clin Oncol* 2011; **29** (Suppl): 3523

79 **Cunningham D**, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; **351**: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]

80 **Peeters M**, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. *Cancer* 2009; **115**: 1544-1554 [PMID: 19189371 DOI: 10.1002/cncr.24088]

81 **Vincenzi B**, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. *Ann Oncol* 2011; **22**: 1141-1146 [PMID: 21115601 DOI: 10.1093/annonc/mdq550]

82 **Vickers MM**, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. *Ann Oncol* 2013; **24**: 953-960 [PMID: 23144444 DOI: 10.1093/annonc/mds577]

83 **Fiorica F**, Berretta M, Ursino S, Fisichella R, Lleshi A, Fiorica G, Stefanelli A, Zini G, Tirelli U, Zanghi A, Cappellani A, Berretta S, Cartei F. Adjuvant radiotherapy on older and oldest breast cancer patients after conservative surgery: a retrospective analysis. *Arch Gerontol Geriatr* 2012; **55**: 283-288 [DOI: 10.1016/j.archger.2011.10.002]

**P-Reviewer:** Lu F, Kato J, Perea J, Yoshida N **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Synopsis of major biomarkers derived from clinical studies for use with epidermal growth-factor receptor-targeted therapies in colorectal cancer chemo, chemotherapy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Biomarkers** | **Prognostic** | **Predictive** | **Predictive efficacy** | **Methodology used** | **Clinical status** |
| EGFR copy number[71] | YES | YES | Raised EGFR gene copy number (GCN) and chromosome 7 polysomy associated with response rate (RR) of 30% *vs* 0% (PAN) | Fluorescence in situ hybridization (FISH) | Awaiting further clinical validation |
| EGFR ligand espresson (epiregulin and amphiregulin)[72,73] | YES | YES | Higher gene-expression profile of ligands in patients with disease control compared to non-responders to CET; odds ratio for response 1.90 for epiregulin and 1.86 for amphiregulin | Gene-expression profiles using RNA and FFPE tumors | Awaiting further clinical validation |
| Activating *KRAS* mutations in codon 12 and 13[48,74] | YES | Predictive for lack of response | Response rate of 12%–17% for *KRAS* WT patients *vs* 0%–1% for *KRAS* mutations (PAN and CET) | PCR on DNA extracted from FFPE samples | FDA-approved clinical biomarker |
| *KRAS* G13D mutations[59,75] | YES | Predictive for lack of response | No difference in response rates between G13D and activating *KRAS* mutations but, 3.6- and 2.1-month improvement in OS and PFS [75] ,improved RR, OR 3.38, 40.5% *vs* 22%[59] (CET + chemo) | PCR on DNA extracted from FFPE samples from multiple studies | Small patient numbers; awaiting results of prospective study (ICECREAM) |
| *NRAS* and *BRAF* mutations[49,76-78] | YES | Predictive for lack of response | Lower RR for *NRAS* and *BRAF* mutations *vs* WT (7.7% and 0%–8.3% *vs* 38% and 17%–47%, respectively) (all *KRAS* WT patients treated with CET and PAN) | Mutation-frequency analysis using PCR and mass spectrometry (FFPE and fresh-frozen samples) | Evidence for significant negative association, but further clinical validation required |
| PIK3CA exon 20 mutations[77] | NO | Predictive for lack of response | 0% *vs* 36.8% RR for exon 20 mutations *vs* WT | Mutation-frequency analysis using PCR and mass spectrometry (FFPE and fresh-frozen samples) | Conflicting evidence when compared to other studies, further validation required |
| Serpin B5 | YES | NO | NO | HE | Awaiting further clinical validation |
| Mucinous histology | YES | YES | NO | HE | Confirmed data |

All figures shown are statistically significant (*P <* 0.05). PAN: Panitumumab; CET: Cetuximab; CRC: Colorectal cancer chemo, chemotherapy; EGFR: Epidermal growth-factor receptor; GCN: Gene copy number; RR: Response rate; RNA: Ribonucleic acid; FFPE: Formalin-fixed paraffin-embedded; WT: Wild type; OS: Overall survival; PFS: Progression-free survival; PCR: Polymerase chain reaction; HE: Histology exam.

**Table 2 Synopsis of major prognostic clinical factors derived from clinical studies on colorectal cancer chemo, chemotherapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Prognostic clinical factors** | **Positive** | **Negative** | **Methodology used** | **Predictive of response to therapy** |
| Age: Young Elderly (according to CGA): Fit Unfit Frail | NOYESNONO | YESNOYESYES | CE | NOSome limitations to choose the T |
| PS-WHO: ≤ 1 ≥ 2 | YESNO | NOYES | CE | NO |
| HIV+ | NO | YES | LT, CE | Poor |
| Advanced clinical state | NO | YES | TNM, CE | NO |
| Elevated CEA levels: Adjuvant Metastatic | NONO | YESYES | LT | NO |
| Elevated Ca19.9 levels | NO | YES | LT | NO |
| Elevated ALP levels | NO | YES | LT | Poor |
| Skin rash[79,80] | YES | YES | HE | Further clinical validation required |
| Hypomagnesaemia[81,82] | Conflicting evidence | Conflicting evidence | Plasma magnesium levels | Further clinical validation required |
| Co-morbidities | NO | YES | ACE-27[83]/CE | Some limitation to choose the T |

CE: Clinical evaluation; LT: Laboratory test; HE: Histology exam; T: Treatment (including surgery, chemotherapy, radiation therapy); TNM: Tumour, lymph nodes, metastases.